Table 4.
Median intraprostatic hormone levels prior to treatment and following 12 weeks of LHRHa plus abiraterone.
| Median tissue androgen (pg/mg) |
Pre- treatment [90% CI] |
LHRHa + bicalutamide |
LHRHa + abiraterone [90% CI] |
% change (pre- treatment vs LHRHa + abiraterone |
p-value |
|---|---|---|---|---|---|
| DHT | 5.92 [5.15–6.80] |
0.798 | 0.050* [0.050-0.050] |
−99% | <0.001 |
| Testosterone | 0.487 [0.372–0.686] |
0.047 | 0.030* [0.030-0.030] |
−94% | <0.001 |
| Androstenedione | 0.305 [0.218–0.449] |
0.648 | 0.010* [0.010-0.010] |
−97% | <0.001 |
| DHEA | 43.7 [28.6–62.7] |
26.3 | 0.660* [0.500–1.23] |
−98% | <0.001 |
| DHEA-S | 0.320 [0.209–0.542] |
-- | 0.0083 [0.0019–0.0182] |
−97% | <0.001 |
| Progesterone | 0.159 [0.112–0.218] |
-- | 1.17 [0.944–1.74] |
636% | <0.001 |
| Pregnenolone | 31.7 [23.4–43.6] |
-- | 244 [183–510] |
670% | <0.001 |
*
indicates levels at the lower limit of detection; --indicates data not available.